The immune response to tumors is malleable as we have learned from the various success of immunotherapies, across a diversity of tumor types. What are the foundations for a solid immune response, particularly one executed by T cells? Imaging and single-cell approaches provide key insights into immune cell types that can be unleashed on tumors, identifying both their identity and the immune interactions that are to be fostered. In considering this, we consider the concepts of seeking "allies" for tumor therapies as well as for understanding the balance of push/pull signals that likely contribute to determine the consensus immune response.We discuss a few of these with particular emphasis on the diversity of the innate immune system and how its component parts can contribute toward antitumor immunity.

Citation Format: Matthew F. Krummel. Cross-presenting DC in the TME [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr SY18-03.